Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials

Trends in Biochemical Sciences

Volumn 35, Issue 1, 2010, Pages 53-61

  Skinner Adams, Tina S ^a,b   Stack, Colin M ^c   Trenholme, Katharine R ^a,b   Brown, Chris L ^b   Grembecka, Jolanta ^d   Lowther, Jonathan ^e   Mucha, Artur ^f   Drag, Marcin ^f   Kafarski, Pawel ^f   McGowan, Sheena ^g   Whisstock, James C ^g   Gardiner, Donald L ^a,b   Dalton, John P ^h  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^g MONASH UNIVERSITY   (Australia)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; BESTATIN; CHLOROQUINE; CYTOSOL AMINOPEPTIDASE; FANSIDAR; HEMOGLOBIN; MICROSOMAL AMINOPEPTIDASE; PHOSPHINIC ACID DERIVATIVE;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; HEMOGLOBIN SYNTHESIS; HUMAN; IC 50; MALARIA FALCIPARUM; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

AMINOPEPTIDASES; ANTIMALARIALS; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

MURINAE; PLASMODIUM FALCIPARUM;

EID: 74049107406     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2009.08.004     Document Type: Review

References (58)

1. Enserink M. Epidemiology. Lower malaria numbers reflect better estimates and a glimmer of hope. Science 321 (2008) 1620
2. Nosten F., et al. Malaria in pregnancy and the endemicity spectrum: what can we learn?. Trends Parasitol. 20 (2004) 425-432
3. Dev V., et al. Malaria parasite burden and treatment seeking behavior in ethnic communities of Assam, Northeastern India. J. Infect. 52 (2006) 131-139
4. Uhlemann A.C., and Krishna S. Antimalarial multi-drug resistance in Asia: mechanisms and assessment. Curr. Top. Microbiol. Immunol. 295 (2005) 39-53
5. Mugittu K., et al. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am. J. Trop. Med. Hyg. 71 (2004) 696-702
6. Marks F., et al. Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine. J. Infect. Dis. 192 (2005) 1962-1965
7. Rogers W.O., et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar. J. 8 (2009) 10
8. Noedl H., et al. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359 (2008) 2619-2620
9. Schlitzer M. Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. Chem. Med. Chem. 2 (2007) 944-986
10. Li X., et al. Plasmodium falciparum signal peptide peptidase is a promising drug target against blood stage malaria. Biochem. Biophys. Res. Commun. 380 (2009) 454-459
11. Gavigan C.S., et al. Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling. Antimicrob. Agents Chemother. 45 (2001) 3175-3181
12. Ersmark K., et al. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. J. Med. Chem. 47 (2004) 110-122
13. Skinner-Adams T.S., et al. Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds. J. Med. Chem. 50 (2007) 6024-6031
14. Li X., et al. BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria. Mol. Biochem. Parasitol. 155 (2007) 26-32
15. Luksch T., et al. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors. Chem. Med. Chem. 3 (2008) 1323-1336
16. Rosenthal P.J., et al. Cysteine proteases of malaria parasites: targets for chemotherapy. Curr. Pharm. Des. 8 (2002) 1659-1672
17. Nezami A., and Freire E. The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors. Int. J. Parasitol. 32 (2002) 1669-1676
18. Ersmark K., et al. Plasmepsins as potential targets for new antimalarial therapy. Med. Res. Rev. 26 (2006) 626-666
19. Loria P., et al. Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. Biochem. J. 339 (1999) 363-370
20. Rosenthal P.J. Hydrolysis of erythrocyte proteins by proteases of malaria parasites. Curr. Opin. Hematol. 9 (2002) 140-145
21. Lew V.L., et al. Excess haemoglobin digestion by malaria parasites: a strategy to prevent premature host cell lysis. Blood Cells Mol. Dis. 32 (2004) 353-359
22. Payne S.H., and Loomis W.F. Retention and loss of amino acid biosynthetic pathways based on analysis of whole-genome sequences. Eukaryot. Cell 5 (2006) 272-276
23. Liu J., et al. Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 8840-8845
24. Martin R.E., and Kirk K. Transport of the essential nutrient isoleucine in human erythrocytes infected with the malaria parasite Plasmodium falciparum. Blood 109 (2007) 2217-2224
25. Howard R.J., et al. Inhibitory effects of histidine analogues on growth and protein synthesis by Plasmodium falciparum in vitro. Biochem. Pharmacol. 35 (1986) 1589-1596
26. Nirmalan N., et al. Quantitative proteomics of the human malaria parasite Plasmodium falciparum and its application to studies of development and inhibition. Mol. Microbiol. 52 (2004) 1187-1199
27. Omara-Opyene A.L., et al. Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. J. Biol. Chem. 279 (2004) 54088-54096
28. Liu J., et al. The role of Plasmodium falciparum food vacuole plasmepsins. J. Biol. Chem. 280 (2005) 1432-1437
29. Sijwali P.S., and Rosenthal P.J. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4384-4389
30. Gardiner D.L., et al. Overexpression of leucyl aminopeptidase in Plasmodium falciparum parasites. Target for the antimalarial activity of bestatin. J. Biol. Chem. 281 (2006) 1741-1745
31. Dalal S., and Klemba M. Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum. J. Biol. Chem. 282 (2007) 35978-35987
32. Cunningham E., et al. Chemical target validation studies of aminopeptidase in malaria parasites using α-aminoalkylphosphonate and phosphonopeptide inhibitors. Antimicrob. Agents Chemother. 52 (2008) 3221-3228
33. McGowan S., et al. Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 2537-2542
34. Kuhn Y., et al. Quantitative pH measurements in Plasmodium falciparum-infected erythrocytes using pHluorin. Cell. Microbiol. 9 (2007) 1004-1013
35. Rosenthal P.J. Cysteine proteases of malaria parasites. Int. J. Parasitol. 34 (2004) 1489-1499
36. Klemba M., et al. A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation. J. Biol. Chem. 279 (2004) 43000-43007
37. Vaughan M.D., et al. Methionine in and out of proteins: targets for drug design. Curr. Med. Chem. 9 (2002) 385-409
38. Chen X., et al. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 14548-14553
39. Korde R., et al. A prodomain peptide of Plasmodium falciparum cysteine protease (falcipain-2) inhibits malaria parasite development. J. Med. Chem. 51 (2008) 3116-3123
40. Jiang S., et al. New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins. Antimicrob. Agents Chemother. 45 (2001) 2577-2584
41. Taylor A. Aminopeptidases: structure and function. FASEB J. 7 (1993) 290-298
42. Matsui M., et al. Leucine aminopeptidases: diversity in structure and function. Biol. Chem. 387 (2006) 1535-1544
43. Gavigan C.S., et al. The role of aminopeptidases in haemoglobin degradation in Plasmodium falciparum-infected erythrocytes. Mol. Biochem. Parasitol. 117 (2001) 37-48
44. Curley G.P., et al. Aminopeptidases from Plasmodium falciparum, Plasmodium chabaudi chabaudi and Plasmodium berghei. J. Eukaryot. Microbiol. 41 (1994) 119-123
45. Kolakovich K.A., et al. Generation of hemoglobin peptides in the acidic digestive vacuole of Plasmodium falciparum implicates peptide transport in amino acid production. Mol. Biochem. Parasitol. 87 (1997) 123-135
46. Gardner M.J., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419 (2002) 498-511
47. Allary M., et al. Properties, stage-dependent expression and localization of Plasmodium falciparum M1 family zinc-aminopeptidase. Parasitology 125 (2002) 1-10
48. Florent I., et al. A Plasmodium falciparum aminopeptidase gene belonging to the M1 family of zinc-metallopeptidases is expressed in erythrocytic stages. Mol. Biochem. Parasitol. 97 (1998) 149-160
49. Stack C.M., et al. Characterization of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development. J. Biol. Chem 282 (2007) 2069-2080
50. Chavagnat F., et al. Purification, characterization, gene cloning, sequencing, and overexpression of aminopeptidase N from Streptococcus thermophilus A. Appl. Environ. Microbiol. 65 (1999) 3001-3007
51. Sherman I.W. Amino acid metabolism and protein synthesis in malarial parasites. Bull. World Health Organ. 55 (1977) 265-276
52. Nankya-Kitaka M.F., et al. Plasmodium chabaudi chabaudi and P. falciparum: inhibition of aminopeptidase and parasite growth by bestatin and nitrobestatin. Parasitol. Res. 84 (1998) 552-558
53. Maric S., et al. The M17 leucine aminopeptidase of the malaria parasite Plasmodium falciparum: importance of active site metal ions in the binding of substrates and inhibitors. Biochemistry 48 (2009) 5435-5439
54. Grembecka J., et al. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity. J. Med. Chem 46 (2003) 2641-2655
55. Flipo M., et al. Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J. Med. Chem. 50 (2007) 1322-1334
56. Harbut M.B., et al. Development of bestatin-based activity-based probes for metallo-aminopeptidases. Bioorg. Med. Chem. Lett. 18 (2008) 5932-5936
57. Van Wart H.E., and Lin S.H. Metal binding stoichiometry and mechanism of metal ion modulation of the activity of porcine kidney leucine aminopeptidase. Biochemistry 20 (1981) 5682-5689
58. Bank U., et al. Triggering endogenous immunosuppressive mechanisms by combined targeting of dipeptidyl peptidase IV (DPIV/CD26) and aminopeptidase N (APN/CD13) - a novel approach for the treatment of inflammatory bowel disease. Int. Immunopharmacol. 6 (2006) 1925-1934